Genmab A/SGMABNASDAQ
Loading
EPS Growth Recovery in ProgressRecovering
Percentile Rank33
Studio
Year-over-Year Change

Year-over-year earnings per share growth rate

Percentile
P33
Within normal range
vs 5Y Ago
-5.9x
Contraction
Streak
1 qtr
Consecutive growthRecovering
PeriodValue
Q4 2025-50.77%
Q3 2025-81.13%
Q2 20251025.82%
Q1 2025-94.89%
Q4 2024207.18%
Q3 2024-10.09%
Q2 20246.90%
Q1 2024107.14%
Q4 2023-69.94%
Q3 202356.73%
Q2 2023550.00%
Q1 2023-64.44%
Q4 2022-77.27%
Q3 202237.02%
Q2 2022307.04%
Q1 2022-35.45%
Q4 2021-19.12%
Q3 2021189.36%
Q2 2021-72.02%
Q1 202190.91%
Q4 20208.64%
Q3 2020-84.39%
Q2 20201165.85%
Q1 2020-82.40%
Q4 2019177.38%
Q3 2019500.00%
Q2 201916.67%
Q1 2019-91.18%
Q4 2018368.97%
Q3 2018-32.56%
Q2 201830.30%
Q1 2018-74.42%
Q4 201714433.33%
Q3 2017-101.76%
Q2 20171788.89%
Q1 2017-98.09%
Q4 2016340.62%
Q3 201614.29%
Q2 20161573.68%
Q1 2016-102.84%